^
    Back
    Association details:
    Biomarker:TNFRSF17 expression
    Cancer:Multiple Myeloma
    Drug:Blenrep (belantamab mafodotin-blmf) (Microtubule inhibitor, BCMA-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    GSK Press Release
    Title:

    US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma

    Published date:
    01/21/2020
    Excerpt:
    GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) granted a priority review for the company’s Biologics License Application (BLA) seeking approval of belantamab mafodotin (GSK2857916) for the treatment of patients with relapsed or refractory multiple myeloma...